For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Dr. Stephanie Lheureux discusses the CCTG OV.25 Ovarian Cancer Trial that explores the possibility of a prevention strategy for ovarian cancer. The OV.25 study targets woman who have the confirmed genetic mutation BRCA1 or BRCA2. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer and researchers want to understand if an anti-inflammatory intervention can help reduce the risk.
The CCTG SRC.6 (COG ARST1321) study is now closed to accrual.
Thanks to the hard work of many across the CCTG group and collaborative working processes with our pediatric colleagues the SRC.6 trial met its primary endpoint early. Addition of pazopanib to preoperative chemoradiation increased rates of complete pathological response for individuals with sarcoma. Additional follow up is planned to determine if this translates into improved event free and overall survival. A huge thank you to everybody who contributed to this success.
MA.39 - Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
The randomization of the first MA.39 patient has been completed by the Juravinski Cancer Centre at Hamilton Health Sciences on October 16, 2018 - Congratulations! This site is lead by the Study Chair Tim Whelan and has four additional patients registered.
The CCTG CEC.5 trial: A Phase II Study of Corticosteroid + Bevacizumab vs Corticosteroid + Placebo (BeST) for Radionecrosis after Radiosurgery for Brain Metastases has officially closed to accrual as of October 12, 2018.
Primary Objective: To investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms (clinical and patient-reported symptom improvement associated with radionecrosis and less radionecrosis treatment-induced symptoms) compared with standard corticosteroid therapy.
A new trial, Nivolumab, Ipilimumab in Patients With Hyper Mutated Cancers Detected in Blood (NIMBLe) will soon open at centers in the US and Canada. Trial researchers will initially explore the use of non-invasive approaches to confirm POLE and POLD1 mutations in solid tumors and to investigate whether those tumors are responsive to immunotherapy.
Why are cancer clinical trials important? Find out in this video interview with Dr. Rebecca Auer.
